Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Decreases By 68.0%

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 70,900 shares, a decline of 68.0% from the September 15th total of 221,800 shares. Based on an average daily volume of 315,800 shares, the short-interest ratio is presently 0.2 days. Approximately 2.8% of the company’s stock are short sold. Approximately 2.8% of the company’s stock are short sold. Based on an average daily volume of 315,800 shares, the short-interest ratio is presently 0.2 days.

VivoSim Labs Stock Performance

VivoSim Labs stock opened at $2.56 on Friday. The stock’s fifty day moving average price is $2.81. The firm has a market cap of $6.66 million, a price-to-earnings ratio of -0.25 and a beta of 1.13. VivoSim Labs has a fifty-two week low of $1.41 and a fifty-two week high of $21.96.

VivoSim Labs (NASDAQ:VIVS) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($1.14) EPS for the quarter. The company had revenue of $0.04 million for the quarter. VivoSim Labs had a negative net margin of 1,396.48% and a negative return on equity of 32.95%.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

VivoSim Labs Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.